• Minocycline HCl for EV Inflammation Workflows

  2026-09-10

  Use Minocycline HCl as a controlled perturbation in extracellular-vesicle, inflammation, and neuroprotection experiments—not merely as an antibiotic. This workflow pairs fresh solution handling, EV-specific controls, and scalable iMSC-EV production concepts to separate drug effects from vesicle-mediated biology.

• Chronic Cabozantinib Signaling Adaptation in RCC

  2026-09-09

  This 2026 study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. It identifies persistent suppression of activating MET phosphorylation alongside selective adhesion-, stress-, and MAPK/AP-1-associated remodeling, with context-dependent changes in migration and invasion.

• Bovine Insulin: Cell Culture Mechanisms & Workflow

  2026-09-09

  Bovine insulin is a double-chain peptide hormone used as a metabolic and trophic supplement in cell culture. Its insulin receptor signaling pathway can support glucose metabolism regulation and cell growth, but product solubility, vehicle controls, and model-specific validation determine experimental reliability.

• Targeted SPP1 Inhibition in Tumor-Associated Myeloid Cells

  2026-09-08

  The reference study identifies a phenotypic small-molecule screening strategy for reducing SPP1 expression in tumor-associated macrophages and integrates promising hits into a TAM-avid CANDI nanoformulation. Its lead compound, CANDI460, reduced SPP1 in vitro and in vivo and produced tumor remissions in multiple murine models, offering a framework for tumor microenvironment macrophage modulation.

• Reserpine (N1867) Lab Workflow Guide

  2026-09-08

  Reserpine (SKU N1867) is a high-purity research compound for controlled neurotransmitter depletion research, antihypertensive mechanism studies, and neuropharmacology workflows. This guide covers identity checks, DMSO preparation, storage, and assay QC; the material is for research use only and is not intended for diagnostic, therapeutic, veterinary, or clinical applications.

• Firefly Luciferase mRNA: A Delivery-Aware Reporter

  2026-09-07

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) provides a sensitive way to separate delivery, translation, and biological response in reporter experiments. This article connects its molecular design with recent gastrointestinal mRNA-LNP delivery research and practical assay decisions.

• Firefly Luciferase mRNA: Workflow & Troubleshooting

  2026-09-07

  Firefly Luciferase mRNA provides a fast, non-integrating control for transfection, expression, viability, and imaging workflows. Its ARCA cap, 5mCTP, pseudouridine, and optimized poly(A) tail support consistent reporter production while making delivery and assay variables easier to diagnose.

• Crizotinib hydrochloride: Assay Reliability Guide

  2026-09-05

  This scenario-based guide explains how Crizotinib hydrochloride (SKU B3608) can improve interpretation of viability, proliferation, and cytotoxicity assays in ALK-, c-Met-, or ROS1-relevant cancer models. It connects kinase-phosphorylation measurements, patient-derived assembloids, formulation handling, and vendor-selection criteria to practical laboratory decisions.

• Exosomal SNORD52 Activates JAK2/STAT6 in HCC

  2026-09-04

  A 2025 Discover Oncology study identifies hepatoma cell-derived exosomal SNORD52 as an intercellular regulator of M2 macrophage polarization in hepatocellular carcinoma. By combining exosome analysis, THP-1 macrophage experiments, qRT-PCR, western blotting, and flow cytometry, the work connects a non-coding RNA cargo to JAK2/STAT6 pathway activation and tumor-microenvironment remodeling.

• Catalpol, Glycolysis, and EphA2/FAK/Src in Liver Fibrosis

  2026-09-04

  A 2024 Phytomedicine study identifies inhibition of aerobic glycolysis in hepatic stellate cells as a key component of catalpol’s antifibrotic activity. The work connects catalpol target engagement at EphA2 with reduced EphA2–FAK association and suppression of downstream FAK/Src signaling, providing a mechanistic framework for evaluating metabolic control of liver fibrosis.

• Chronic Cabozantinib Phosphoproteomics in RCC

  2026-09-03

  This 2026 study uses quantitative phosphoproteomics to distinguish acute from chronic Cabozantinib adaptation in renal cell carcinoma cells. Its main contribution is showing that long-term exposure preserves MET activation-loop suppression while selectively reshaping adhesion-, stress-, and MAPK/AP-1-associated phosphorylation programs linked to modest, context-dependent motility changes.

• Optimized hiPSC Platelet Differentiation: Key Findings

  2026-09-03

  Yue et al. developed an optimized differentiation scheme that increases megakaryocyte and platelet production from human induced pluripotent stem cells while shortening culture time and reducing cost. The study combines higher embryoid body input, human platelet lysate, cytokine-replacing small molecules, and maturation-promoting compounds to generate functional platelets with measurable clot-forming activity.

• PMSF Protein Extraction Workflow & Troubleshooting

  2026-09-02

  Learn how PMSF protects protein extracts, supports Western blot sample preparation, and improves interpretation of signaling assays. This practical guide combines selective serine protease inhibition with a shrimp hemocyte and extracellular-vesicle research use case, while emphasizing controls, fresh preparation, and troubleshooting.

• NHE1 Links Octanal–Olfr2 Signaling to Atherosclerosis

  2026-09-02

  This Scientific Reports study identifies macrophage NHE1 as a downstream effector of octanal–Olfr2 signaling in atherosclerosis, connecting calcium influx with ROS production, NLRP3 inflammasome activity, foam-cell formation, and vascular inflammation. Its combined mouse, macrophage, inhibition, RNA interference, and calcium-chelation experiments provide a mechanistic framework for evaluating NHE1 as a potential intervention point.

• Rifampin: Mechanism and Research Workflow

  2026-09-01

  Rifampin is a rifamycin antibiotic and DNA-dependent RNA polymerase inhibitor that blocks bacterial transcription. Its defined target, resistance genetics, and practical DMSO handling support bacterial resistance mechanism research, transcriptional regulation studies, and synthetic biology transcription inhibition.

8541 records 5/570 page Previous Next 12345 下5页 Last page